GILEAD SCIENCES INC (GIS.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:GIS - US3755581036 - Common Stock
GIS.DE Key Statistics, Chart & Performance
The current stock price of GIS.DE is 104.9 EUR. In the past month the price decreased by -0.34%. In the past year, price increased by 21.92%.
GIS.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 65.47 | 42.89B | ||
| ARGX.BR | ARGENX SE | 65.51 | 42.91B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.56B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.72B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.72B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.87B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| NANO.PA | NANOBIOTIX | N/A | 838.95M | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| IVA.PA | INVENTIVA SA | N/A | 778.40M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M |
Related stock screener links
About GIS.DE
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
Company Info
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA US
Employees: 17600
Phone: 16505743000
GILEAD SCIENCES INC / GIS.DE FAQ
What does GIS do?
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
What is the stock price of GILEAD SCIENCES INC today?
The current stock price of GIS.DE is 104.9 EUR. The price decreased by -0.68% in the last trading session.
Does GILEAD SCIENCES INC pay dividends?
GILEAD SCIENCES INC (GIS.DE) has a dividend yield of 2.57%. The yearly dividend amount is currently 2.68.
How is the ChartMill rating for GILEAD SCIENCES INC?
GIS.DE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about GILEAD SCIENCES INC (GIS.DE) stock?
37 analysts have analysed GIS.DE and the average price target is 116.75 EUR. This implies a price increase of 11.3% is expected in the next year compared to the current price of 104.9.
Would investing in GILEAD SCIENCES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GIS.DE.
What is the employee count for GIS stock?
GILEAD SCIENCES INC (GIS.DE) currently has 17600 employees.
GIS.DE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to GIS.DE. When comparing the yearly performance of all stocks, GIS.DE is one of the better performing stocks in the market, outperforming 73.54% of all stocks.
GIS.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GIS.DE. GIS.DE scores excellent on profitability, but there are some minor concerns on its financial health.
GIS.DE Financial Highlights
Over the last trailing twelve months GIS.DE reported a non-GAAP Earnings per Share(EPS) of 7.01. The EPS increased by 84.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.88% | ||
| ROA | 13.86% | ||
| ROE | 37.8% | ||
| Debt/Equity | 0 |
GIS.DE Forecast & Estimates
37 analysts have analysed GIS.DE and the average price target is 116.75 EUR. This implies a price increase of 11.3% is expected in the next year compared to the current price of 104.9.
For the next year, analysts expect an EPS growth of 80.6% and a revenue growth 3.16% for GIS.DE